Valuation : OSE Immunotherapeutics

Market Cap 75.83M 88.34M 70.99M 65.01M 122M 8.44B 123M 841M 329M 4.25B 332M 324M 14.07B P/E 2026 *
-2.47x
P/E 2027 * -2.83x
Enterprise Value 117M 136M 109M 99.98M 188M 12.98B 189M 1.29B 505M 6.54B 510M 499M 21.64B EV / Sales 2026 *
23.8x
EV / Sales 2027 * 13.2x
Free-Float
78.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : OSE Immunotherapeutics

1 day+0.25%
1 week-4.45%
Current month+0.56%
1 month+2.03%
3 months-34.36%
6 months-27.22%
Current year-37.40%
1 week 3.16
Extreme 3.162
3.35
1 month 3.16
Extreme 3.156
3.54
Current year 2.87
Extreme 2.872
5.9
1 year 2.87
Extreme 2.872
7.7
3 years 2.71
Extreme 2.71
11.58
5 years 2.7
Extreme 2.705
13.68
10 years 2.7
Extreme 2.7
15.8
Manager TitleAgeSince
Chief Executive Officer - 01/10/2025
Director of Finance/CFO 43 19/08/2025
Chief Tech/Sci/R&D Officer - 19/12/2021
Director TitleAgeSince
Director/Board Member 77 30/05/2016
Director/Board Member 73 13/06/2017
Director/Board Member - 21/06/2023
Date Insider Type Main position Quantity % Market Cap.
13/11/24 Sell

Director

30,000 0.1375%
12/11/24 Sell

Chief Administrative Officer

10,000 0.0458%
21/06/24 Fiscal year

Director

10,000 0.0459%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-4.45%-47.23%+15.56% 88.13M
+0.10%+1.59%+1.76%+24.32% 50.96B
+2.65%+3.02%+493.29%+567.32% 46.18B
-0.88%-1.16%+20.58%+87.74% 42.73B
+0.33%+5.26%+39.74%+19.80% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%+0.54%+30.32%+135.38% 17.28B
-0.36%-3.95% - - 16.43B
+0.25%+3.31%+11.38%+30.68% 14.73B
+0.44%+2.21%+81.06%+47.92% 14.09B
Average +0.08%+0.73%+71.68%+108.91% 27.9B
Weighted average by Cap. +0.29%+1.16%+105.74%+141.79%

Financials

2026 *2027 *
Net sales 4.9M 5.71M 4.59M 4.2M 7.91M 545M 7.94M 54.32M 21.24M 275M 21.43M 20.97M 909M 10.53M 12.27M 9.86M 9.03M 17.01M 1.17B 17.05M 117M 45.63M 590M 46.06M 45.06M 1.95B
Net income -30.59M -35.63M -28.64M -26.22M -49.39M -3.4B -49.53M -339M -133M -1.72B -134M -131M -5.68B -21.47M -25.01M -20.1M -18.4M -34.67M -2.39B -34.77M -238M -93.03M -1.2B -93.89M -91.86M -3.98B
Net Debt 40.79M 47.52M 38.19M 34.97M 65.87M 4.54B 66.06M 452M 177M 2.29B 178M 175M 7.57B 63.08M 73.49M 59.06M 54.08M 102M 7.02B 102M 699M 273M 3.54B 276M 270M 11.71B
Logo OSE Immunotherapeutics
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes: - Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors; - OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia; - FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes); - BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms: - Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I; - Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO; - Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Employees
64
Date Price Change Volume
27/08/26 3.224 +0.25% 80,728
26/08/26 €3.216 +0.12% 57,101
25/08/26 €3.212 +0.75% 72,226
24/08/26 €3.188 -4.38% 112,844
21/08/26 €3.334 -0.30% 115,625
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.216EUR
Average target price
12.70EUR
Spread / Average Target
+294.90%

Annual profits - Rate of surprise